Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) shares traded 1.61% higher at $1.26 on Wall Street last session.
ZNTL stock price is now -5.48% away from the 50-day moving average and -46.16% away from the 200-day moving average. The market capitalization of the company currently stands at $90.66M.
With the price target maintained at $4, Wedbush recently Upgraded its rating from Underperform to Neutral for Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL). On June 20, 2024, UBS Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $28 to quote $5, while ‘Wells Fargo’ rates the stock as ‘Equal Weight’
In other news, Myers Scott Dunseth, Director bought 21,000 shares of the company’s stock on Apr 30 ’25. The stock was bought for $29,373 at an average price of $1.40. Upon completion of the transaction, the Director now directly owns 281,192 shares in the company, valued at $0.35 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 06 ’25, Chief Medical Officer Bruns Ingmar bought 20,000 shares of the business’s stock. A total of $45,656 was incurred on buying the stock at an average price of $2.28. This leaves the insider owning 36,629 shares of the company worth $46152.54. A total of 22.85% of the company’s stock is owned by insiders.
During the past 12 months, Zentalis Pharmaceuticals Inc has had a low of $1.01 and a high of $5.44. As of last week, the company has a debt-to-equity ratio of 0.13, a current ratio of 6.94, and a quick ratio of 6.94. The fifty day moving average price for ZNTL is $1.333 and a two-hundred day moving average price translates $2.340225 for the stock.
The latest earnings results from Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) was released for 2025-03-31. The net profit margin was -834.49% and return on equity was -59.45% for ZNTL.
